Viewing nowCombinationDapael Duo Sustained-Release Tablets 10/500 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.

MFDS item code 202301900 · Approved 2023.06.21 · Insurance code 647304530
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes by combining dapagliflozin and metformin. It can effectively control blood sugar levels when used in conjunction with dietary and exercise therapy. It is especially suitable for patients with cardiovascular disease or risk factors, and in such cases, it is important to consult a doctor regarding the cardiovascular effects of dapagliflozin. Thus, this medication is helpful in managing both blood sugar levels and cardiovascular health.
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy alone: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose of this medication may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dosage adjustments made as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering agents. Because changes may lead to alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. In some cases, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is likely to decline in elderly patients, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used in the treatment of type 2 diabetes to help control blood sugar levels. It can rarely cause a dangerous condition known as lactic acidosis, so patients with poor kidney function, severe infections, dehydration, or cardiovascular issues should not use it. In addition, when used with insulin or other diabetes medications, there is a risk of hypoglycemia, so caution is necessary. Patients with impaired kidney function or the elderly should use this medication cautiously, and kidney function and fluid status should be frequently monitored before and during use. Women who are pregnant or breastfeeding should not take this medication, and its safety in children has not been established. This medication may increase the risk of genital and urinary tract infections, so if symptoms of infection occur, patients should consult a doctor immediately. Signs of decreased fluid volume or low blood pressure may occur, so it is important to periodically check blood pressure and fluid status. Vitamin B12 deficiency may develop, so it is advisable to check blood vitamin B12 levels during prolonged use. Excessive alcohol consumption should be avoided while taking this medication, and if undergoing surgery or imaging tests, it should be discontinued for a certain period. Also, this medication may interact with other drugs, so if taking other medications, it is essential to inform the doctor or pharmacist. In case of overdose, seek medical attention immediately, and this medication should be kept out of the reach of children. There may be symptoms like dizziness when driving or operating machinery, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is best to maintain a storage temperature between 1 and 30 degrees Celsius.
Pink, double convex, oval-shaped sustained-release film-coated tablets
30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.